Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Trial Profile

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FLX-475 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Colorectal cancer; Epstein-Barr virus infections; Gastric cancer; Head and neck cancer; Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors RAPT Therapeutics
  • Most Recent Events

    • 24 May 2019 According to an FLX Bio media release, the company expects the proof-of-concept data from this study in the first half of 2020.
    • 24 May 2019 According to an FLX Bio media release, the company has changed its name to RAPT Therapeutics.
    • 20 May 2019 According to a Personalis media release, company has entered into a research agreement with FLX Bio. Under the terms of the agreement, FLX Bio will utilize Personalis universal cancer immunogenomics platform, ImmunoID NeXT, to evaluate therapy-related changes in tumors of advanced cancer patients participating in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top